H107e/CAF®10b is being developed by SSI and is a next-generation TB subunit vaccine incorporating 8 different Mtb antigens in a novel liposomal Th1/Th17 inducing adjuvant. It is specifically designed to complement a BCG response with novel T cells against Mtb-specific antigens and comes with the option of BCG co-administration.